Charles River Laboratories shares were lower Friday (March 27, 2026), tracking a risk-off tape but also reacting to renewed focus on near-term earnings risk. The key incremental driver is a round of forecast revisions that cut expectations for Q1 2026 profitability, pressuring sentiment into the next earnings window. (marketbeat.com)

A recently published research update lowered its Q1 2026 EPS view to $2.05 from $2.39, flagging potential near-term weakness even as longer-dated estimates were raised. For traders, that combination often translates into “near-term air pocket” concerns—particularly if the market begins to anchor on the next quarter rather than full-year targets. (marketbeat.com)

Separately, the company’s planned divestitures continue to reset headline growth optics for 2026. The transactions are expected to reduce reported revenue by slightly more than $200 million in 2026 while management simultaneously pointed to margin improvement and an updated non-GAAP EPS range of about $10.80 to $11.30—creating an ongoing push-pull between near-term demand uncertainty and longer-term profitability reshaping. (investing.com)

The next major catalyst is the upcoming earnings report, which market calendars currently peg for early May 2026. With the stock reacting to quarterly EPS sensitivity, investors will likely focus on (1) order trends in core services, (2) any further changes to 2026 guidance as divestitures progress, and (3) signs that cost actions are translating into sustainable operating margin gains. (marketbeat.com)